The European Medicines Agency (EMA) has recommended strengthening existing advice to minimize the risks from interactions between Mysimba (naltrexone/bupropion; Orexigen Therapeutics Ireland Limited) and opioid-containing medicines. The recommendation followed a routine review of the safety of the weight loss medication. The EMA’s Committee for Medicinal Products for Human Use (CHMP) advised that opioid painkillers may …
